Veeva SystemsVEEV
Recorded

Veeva Systems Investor Day 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration2 hr 18 minParticipants22

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Gunnar HansenSenior Director and Head of Investor Relations

Before we get started, I will read a quick disclaimer. During the course of today's presentations, we will make forward-looking statements, including statements regarding trends, our strategies, market size and opportunities, and the anticipated performance of our business, including guidance regarding future financial results. These forward-looking statements are based on management's current views and expectations and are subject to various risks and uncertainties. Actual results may differ materially. Please refer to the risk factors included in our most recent filing on Form 10-Q. Forward-looking statements made during today's presentations are being made as of today, November 5, 2026. If the presentations are replayed or viewed after today, the information presented may not contain current or accurate information. Veeva disclaims any obligation to update or revise any forward-looking statements. In the presentation, we will also discuss certain non-GAAP metrics that we believe aid in the understanding of our financial results.

Gunnar HansenSenior Director and Head of Investor Relations

A reconciliation to comparable GAAP metrics can be found in the appendix of today's presentation, which will be posted on our website. With that, I will turn it over to our founder and CEO, Peter Gassner.

Peter GassnerFounder and CEO

Thanks, Gunnar, and welcome everyone to our Investor Day. I will start it out with our vision and values. This is our strategy on the slide. Start with our vision, which is what we are doing. We are building the industry cloud for life sciences. That is software, AI, data, and consulting to help the industry be more efficient and effective. We want to help our customers bring more of the right medicines and medical devices to patients around the world. We want to be essential to and appreciated by every company in life sciences. That is a high bar. It is what we are striving to do, and this is what energizes us every day. Our values are how we make decisions along the way. The first is do the right thing. That is having the right honesty and integrity about actively knowing what the right thing is and doing it. Customer success has three parts.

Peter GassnerFounder and CEO

That is for the people in the industry. They have to enjoy working with our people and our products. Second is for the companies in the industry. They have to get positive ROI out of our products and services. Third is the industry overall. Veeva has to be a positive force for the industry and help the industry grow. Employee success, that is for our team, has to be a place where our team can do their best work. Speed reminds us to do things quickly and correctly with high quality the first time. That way, we can retain that speed, that startup speed, even as we grow bigger. Finally, we are a public benefit corporation. That means we have a legal duty, yes, to our investors, but also to our customers, to our employees, and to society in general.

Peter GassnerFounder and CEO

We have to balance the interests of all concerned, and that's a great thing to do here because what we're building is a long-term company that's providing a lot of value to the world and to our investors. Highlights you'll hear today. First, you'll hear about the golden age of life sciences, how the industry's really set to grow, and we'll grow along with that. You'll hear about our strong execution, but also our innovation in new areas, for example, our AI solutions. We'll talk about industry AI specifically as a big opportunity, and yes, we'll also hear that we're on track for our $6 billion revenue run rate goal in calendar 2030. We are a strategic partner to the life sciences industry, a strategic technology partner, and it's a critical industry, a very resilient industry, and it's a big industry.

Peter GassnerFounder and CEO

Well over $2 trillion, this industry, pharma and biotech, and it's growing at 6%, and I think it will continue to grow in the future as technology advances. It's a growing opportunity for Veeva as well. We view our opportunity as a $30 billion TAM, and that's up from $20 billion last year. That's largely because of AI. AI is a new technology. It's a new technology paradigm. It's probabilistic computing. It allows reasoning. It allows us to do things we haven't been able to do before, to help the industry in new ways with AI solutions that work with our applications and our data and our consulting, and that's why our TAM is growing by $10 billion, in fact, and we're really energized about that. How can we bring AI to bear to help the industry bring more of the right medicines to patients?

Peter GassnerFounder and CEO

When I talk about the golden age of life sciences, I really break it down this way. First, AI is really enabling drug discovery, industry-specific models that know about biology. Of course, the frontier models are adding understanding of biology all the time into their models, so that's really, really going to help in the drug discovery area. Also, AI is empowering patients and doctors to be more informed about these very specific medicines and therapeutic areas, and how does it relate to them as a doctor or them as a patient? So doctors and patients getting more informed, that's going to mean more of the medicines and better medicines getting to patients. That means life sciences is going to create more value for the world, and I think the industry will grow along with that.

Peter GassnerFounder and CEO

That's why I call this the golden age of life sciences, really enabled by AI in these multiple areas. In terms of our product offerings, our industry cloud for life sciences, we're organized around four clouds: the Development Cloud, Quality Cloud, Commercial Cloud, and Data Cloud. We have our business consulting that spans across all our offerings and helps our customers get value out of our products, because when you put our products in, you might need to change your business processes and measure what you're doing and do that change management. Then also Falcon, our agentic labor, and that runs across all of our different clouds. I'll talk a little bit about each area. But first, that's our product strategy, but what is our long-term strategy? What are we trying to do with these products? Where are we going? Veeva's been here for almost 20 years, and we got a long runway ahead if you look at our next 20 years or so, our foreseeable future.

Peter GassnerFounder and CEO

We want to complete the industry cloud. A lot of these applications are young, they have to get more robust, and we have to keep them current all the time. That's job number one, complete that industry cloud, connect those applications together. We also want to connect the industry out to their customers, out to research sites, regulators, doctors, patients, health systems, contract manufacturers. The life sciences industry does not live in a silo. It's part of a connected workflow that's get out to all these other organizations. We view that as our job to do that, to enable that connectivity. Finally, deliver AI, industry-specific AI for the industry.

Peter GassnerFounder and CEO

Not just create it, deliver it, connect it with our applications, connect it with our data, and help the customers get value, real value out of these applications, and make it sustainable, compliant, and validated over the long term. So it's delivering AI, not talking about exploring with AI, delivering AI over the long term. The whole Veeva team is very clear on this strategy for life sciences, these three things: complete the industry cloud, connect the industry, and deliver AI for the industry. Let's start with Development Cloud. This is a lot of different applications in here, organized in clinical operations, clinical data management, regulatory, and safety. We have some very mature applications, TMF, over 500 customers, some new applications, labeling, which we're just introducing, have very few, zero customers as of yet.

Peter GassnerFounder and CEO

They're in all levels of maturity, but our goal is product excellence on each one. So we have dedicated product managers, dedicated strategy teams, developers, support people, consultants that know these areas, services people that know these areas. We like to get specific and solve these problems. We're providing this important technology blueprint for the industry here in Development Cloud, big undertaking that nobody else has really tried before. We started this roughly 15 years ago with this idea that we're going to make this, and now it's coming to fruition. Still has a long way to go, but we're really happy with the progress, and all built, of course, on our Veeva Vault Platform. If I dive down into one area, I want to talk about this Veeva Clinical Network. That's part of connecting the industry. This is connecting research sites to sponsors, to biopharma companies.

Peter GassnerFounder and CEO

For research sites, we have our SiteVault suite of applications, and the research sites also have their electronic health record system. Sponsors, they're running clinical trials. They are clinical operation systems, our clinical data management systems, and we're providing the connectivity there. For example, in SiteVault, we have our brand new eSource application, collecting the data from the EMR, from the directly entered data in the sites directly into our EDC. That's eSource, that eliminates paper, reduces costs, and increases speed. It takes a big partner like Veeva to connect these industries, research sites, and sponsors seamlessly. We're really excited about this. People have tried this for a long time. They haven't been able to do it, but why do I think we can do it?

Peter GassnerFounder and CEO

One, we're attacking it comprehensively at the sites to automate their work, at the sponsors to automate their work, connecting the dots together. Also, we have the trust, both of the sites and the sponsors, because we've been doing this for a long time, and we've earned that trust. The industry wants this to happen because they know that this means they can run more clinical trials. Also, we have Veeva Study Suite, and this is really going to unlock a great opportunity in the CRO channel, because smaller biotechs, oftentimes, they may outsource the trial. They cannot operate the technology themselves, not just the technology, the whole business process of running a trial, so they may outsource this to a CRO.

Peter GassnerFounder and CEO

What we're going to do with Study Suite is offer a very easy method for the CROs to offer the full suite of applications to a sponsor and run that trial with our technology, pass it through to the small biotech. This is an area we haven't focused on. We believe this is well over a billion-dollar opportunity just in the EDC, the eCOA, the RTSM area. This is actually a billion-dollar opportunity because almost half of the trials are outsourced, and that's an area we just hadn't focused on yet. So, we're really going to focus on this area, and the nice thing is that many, many of the CROs use our Clinical Operations Suite already, and our clinical data applications are integrated right into our Clinical Operations Suite, which fits right into the eTMF of the small sponsors.

Peter GassnerFounder and CEO

This is really set up for success, and we're hiring a dedicated team to go after this. Couldn't be more excited. Also, this plays into our great partnership that we announced with IQVIA recently around their selecting our Clinical Operations Suite. So, really excited about what we can do here. It's time for Veeva to really deliver through this channel. All right, let's talk about Quality Cloud, a super exciting area. There's really three parts of Quality Cloud. Quality assurance, that's where we've been for a long time. Our flagship applications there are QualityDocs and QMS, and we have other applications like Training, Validation, and Batch Release. Then quality control, brand new area for us. This is LIMS, what's called QC LIMS. This is where you're testing the medicines as they're being manufactured, after they're manufactured, to make sure they meet the specifications.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day